Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
ARDX

ARDX - Ardelyx Inc Stock Price, Fair Value and News

$7.88-0.01 (-0.13%)
Market Closed

59/100

ARDX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

59/100

ARDX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$8.45

Target 3M

$7.93

Target 6M

$8.1

ARDX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ARDX Price Action

Last 7 days

-1.4%

Last 30 days

36.3%

Last 90 days

57.3%

Trailing 12 Months

43.5%

ARDX RSI Chart

ARDX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ARDX Valuation

Market Cap

1.9B

Price/Earnings (Trailing)

-33.86

Price/Sales (Trailing)

4.81

EV/EBITDA

-49.79

Price/Free Cashflow

-34.59

ARDX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$8.45

Target 3M

$7.93

Target 6M

$8.1

ARDX Fundamentals

ARDX Revenue

Revenue (TTM)

398.2M

Rev. Growth (Yr)

12.3%

Rev. Growth (Qtr)

12.97%

ARDX Earnings

Earnings (TTM)

-56.5M

Earnings Growth (Yr)

-19.78%

Earnings Growth (Qtr)

94.92%

ARDX Profitability

Operating Margin

98.60%

EBT Margin

-13.95%

Return on Equity

-36.65%

Return on Assets

-11.63%

Free Cashflow Yield

-2.89%

ARDX Investor Care

Shares Dilution (1Y)

2.58%

Diluted EPS (TTM)

-0.23

ARDX Alerts

  • 1 major insider sales recently.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025361.7M386.1M398.2M0
2024159.1M210.0M251.8M333.6M
202363.1M82.9M134.3M124.5M
20224.0M5.2M9.0M52.2M
202112.9M12.4M10.9M10.1M
20206.6M8.3M8.0M7.6M
2019003.3M5.5M
201844.3M44.4M44.5M2.6M
201700060.1M
201529.0M38.0M30.4M24.0M
201430.9M32.8M33.8M31.6M
201311.3M17.2M23.0M28.9M
20120005.4M
Get all data in R, Python etc through our Historical Stock Data APIs

About Ardelyx Inc

ARDX
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
 CEO
 WEBSITEardelyx.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES133

Ardelyx Inc Frequently Asked Questions

ARDX is the stock ticker symbol of Ardelyx Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Ardelyx Inc is 1.91 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check ARDX's fair value in chart for subscribers.

The fair value guage provides a quick view whether ARDX is over valued or under valued. Whether Ardelyx Inc is cheap or expensive depends on the assumptions which impact Ardelyx Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ARDX.

As of Wed Jan 28 2026, ARDX's PE ratio (Price to Earnings) is -33.86 and Price to Sales (PS) ratio is 4.81. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ARDX PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Ardelyx Inc has provided -0.028 (multiply by 100 for percentage) rate of return.